Educational article
Semaglutide and cardiovascular risk: what SELECT found
Educational content. It does not replace an individual medical assessment and should not be used for self-medication.

Who the trial studied
SELECT enrolled adults with overweight or obesity and established cardiovascular disease, without diabetes. It compared injectable semaglutide with placebo alongside usual care.
What the study observed
The semaglutide group had fewer events in the combined outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke. Baseline risk matters when interpreting the result.
What to ask at a visit
Ask whether your situation resembles the study population and what goal treatment would serve. The findings apply to the formulation studied. Ask for separate evidence about tablets or other medicines.
When to seek medical care
If symptoms persist, test results are abnormal, or you have questions about medication, arrange an individual assessment. Do not change treatment or doses without medical guidance.
Frequently asked questions
Does the trial mean I can stop other heart medicines?
The trial added treatment to usual care. Discuss any changes with your cardiovascular team.
References
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes · New England Journal of Medicine
- Prescription Medications to Treat Overweight & Obesity · NIDDK
Does this topic resonate with you?
Every case is different. Book a consultation to review your history, test results and goals with a personalized plan.


